| CVRx, Inc. (CVRX) Q1 2025 Earnings Conference Call Transcript |
CVRx, Inc. (NASDAQ:CVRX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Kevin Hykes - President & CEO Jared Oasheim - CFO Mike Vallie - IR, ICR Healthcare Conference Call Participants Macauley Kilbane - William Blair Nelson Cox - Lake Street Capital Markets Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald Operator Good day, everyone, and welcome to today's CVRx Q1 2025 earnings call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-10 19:51:50 |
Czytaj oryginał (ang.) |
| CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates |
CVRx (CVRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $1.04 per share a year ago. |
zacks.com |
2025-05-08 23:35:37 |
Czytaj oryginał (ang.) |
| CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release |
CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-01 15:07:43 |
Czytaj oryginał (ang.) |
| CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025 |
MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. |
globenewswire.com |
2025-04-24 20:30:00 |
Czytaj oryginał (ang.) |
| CVRx Inc: Overreaction Creates Buying Opportunity |
CVRx Inc. stock has recently dropped 40%, presenting a buying opportunity as the long-term growth potential remains intact. Barostim has strong clinical results and significant market potential, with a $2.2 billion TAM. Average selling prices can potentially improve as the market recognizes Barostim's effectiveness. |
seekingalpha.com |
2025-04-09 12:45:06 |
Czytaj oryginał (ang.) |
| Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session |
U.S. stock futures were higher this morning, with the Dow futures gaining more than 900 points on Tuesday. |
benzinga.com |
2025-04-08 12:35:36 |
Czytaj oryginał (ang.) |
| CVRx Reports Preliminary First Quarter 2025 Financial Results |
First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024 First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024 |
globenewswire.com |
2025-04-07 20:05:00 |
Czytaj oryginał (ang.) |
| CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim |
New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction |
globenewswire.com |
2025-02-12 16:45:00 |
Czytaj oryginał (ang.) |
| CVRx (CVRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? |
CVRx (CVRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
zacks.com |
2025-02-11 12:56:19 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 25.76% Upside in CVRx (CVRX): Here's What You Should Know |
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in CVRx (CVRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-02-07 12:56:23 |
Czytaj oryginał (ang.) |
| CVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call Transcript |
CVRx, Inc. (NASDAQ:CVRX ) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ET Company Participants Mike Vallie - Investor Relations, ICR Healthcare Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Macauley Kilbane - William Blair William Plovanic - Canaccord Genuity Samantha Munoz - Piper Sandler Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to the CVRx Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-02-05 01:00:22 |
Czytaj oryginał (ang.) |
| CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates |
CVRx (CVRX) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.44 per share a year ago. |
zacks.com |
2025-02-04 20:46:32 |
Czytaj oryginał (ang.) |
| CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results |
MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2024. |
globenewswire.com |
2025-02-04 18:05:00 |
Czytaj oryginał (ang.) |
| CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025 |
MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2024 financial and operating results after market close on Tuesday, February 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. |
globenewswire.com |
2025-01-21 18:30:00 |
Czytaj oryginał (ang.) |
| CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy? |
CVRx (CVRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-01-16 13:06:24 |
Czytaj oryginał (ang.) |
| CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. The Company is scheduled to present at 2:15 PM Pacific Time the same day via webcast. |
globenewswire.com |
2024-12-23 18:30:00 |
Czytaj oryginał (ang.) |
| CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference |
MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast. |
globenewswire.com |
2024-11-20 18:30:00 |
Czytaj oryginał (ang.) |
| CVRx: Impressive Top-Line Growth Seems Priced In |
CVRx's Barostim therapy shows strong clinical success and impressive revenue growth. Recent reimbursement approvals from CMS enhance Barostim's sales potential. Despite double-digit sales growth and a promising product, CVRx's path to profitability is hindered by escalating SG&A costs and potential future shareholder dilution. |
seekingalpha.com |
2024-11-06 23:04:21 |
Czytaj oryginał (ang.) |
| CVRx, Inc. (CVRX) Q3 2024 Earnings Call Transcript |
CVRx, Inc. (NASDAQ:CVRX ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Mike Vallie - Investor Relations Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Macauley Kilbane - William Blair Rohin Patel - JPMorgan Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald. Operator Welcome to CVRx Q3 2024 Earnings Call. |
seekingalpha.com |
2024-10-30 00:38:09 |
Czytaj oryginał (ang.) |
| CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates |
CVRx (CVRX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.43 per share a year ago. |
zacks.com |
2024-10-29 20:50:28 |
Czytaj oryginał (ang.) |
| CVRx (CVRX) Soars 17.2%: Is Further Upside Left in the Stock? |
CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-10-21 13:45:14 |
Czytaj oryginał (ang.) |
| CVRx announces new CPT® Category I codes for Barostim |
MINNEAPOLIS, Oct. 18, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the American Medical Association (AMA) CPT® Editorial Panel has accepted new Current Procedural Terminology (CPT) Category I codes for baroreflex activation therapy (“Barostim”) to treat the symptoms of heart failure. |
globenewswire.com |
2024-10-18 18:08:00 |
Czytaj oryginał (ang.) |
| CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024 |
MINNEAPOLIS, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release third quarter 2024 financial and operating results after market close on Tuesday, October 29, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. |
globenewswire.com |
2024-10-15 20:30:00 |
Czytaj oryginał (ang.) |
| CVRX Stock Gains on Unveiling of Barostim's Positive Study Data |
CVRx announces the publication of positive study data for its Barostim therapy. |
zacks.com |
2024-09-16 15:40:18 |
Czytaj oryginał (ang.) |
| CVRx Announces Appointment of Two New Board Members |
Kevin Ballinger and Mitch Hill appointed as new independent Board members Kevin Ballinger and Mitch Hill appointed as new independent Board members |
globenewswire.com |
2024-09-03 12:30:00 |
Czytaj oryginał (ang.) |
| CVRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Clients to Contact the Firm! |
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX. |
accesswire.com |
2024-08-21 14:00:00 |
Czytaj oryginał (ang.) |
| CVRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Shareholders to Contact the Firm Today! |
NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX. |
accesswire.com |
2024-08-20 14:00:00 |
Czytaj oryginał (ang.) |
| CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings |
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. (“CVRx” or “the Company”) (NASDAQ: CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX. |
globenewswire.com |
2024-08-19 20:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX |
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ:CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-08-19 17:15:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Is Investigating CVRx Inc For Securities Fraud And Urging Investors To Join |
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-08-19 15:00:00 |
Czytaj oryginał (ang.) |
| CVRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Shareholders to Contact the Firm Today! |
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX. |
accesswire.com |
2024-08-19 14:00:00 |
Czytaj oryginał (ang.) |
| CVRX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Investors to Contact the Firm Today! |
NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX. |
accesswire.com |
2024-08-18 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX |
NEW YORK , Aug. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-08-18 03:05:00 |
Czytaj oryginał (ang.) |
| CVRx Inc Shareholders Can Join Fraud Investigation With The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-08-17 15:00:00 |
Czytaj oryginał (ang.) |
| CVRx Inc Investors Encouraged To Participate In Fraud Inquiry With The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-08-16 15:00:00 |
Czytaj oryginał (ang.) |